EICHOR
● Terminated
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica
Condition: Pruritus · Notalgia Paresthetica · Sponsor: Cara Therapeutics, Inc.
About this study
This is a 2-part, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of twice-daily (BID) oral difelikefalin for moderate-to-severe pruritus in adult subjects with NP.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (58)
| Cara Therapeutics Study Site | Birmingham, Alabama, United States | — |
| Cara Therapeutics Study Site | Phoenix, Arizona, United States | — |
| Cara Therapeutics Study Site | Fayetteville, Arkansas, United States | — |
| Cara Therapeutics Study Site | Hot Springs, Arkansas, United States | — |
| Cara Therapeutics Study Site | Encino, California, United States | — |
| Cara Therapeutics Study Site | Fountain Valley, California, United States | — |
| Cara Therapeutics Study Site | Los Angeles, California, United States | — |
| Cara Therapeutics Study Site | Northridge, California, United States | — |
| Cara Therapeutics Study Site | Valencia, California, United States | — |
| Cara Therapeutics Study Site | Coral Gables, Florida, United States | — |
| Cara Therapeutics Study Site | Hollywood, Florida, United States | — |
| Cara Therapeutics Study Site | Lutz, Florida, United States | — |
+ 46 more locations — full list on the registry record.
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05978063